(3 minutes read)
The Indian government had told Maiden Pharmaceuticals to stop its production after the disaster in the Gambia when children died after consuming the cough syrup manufactured by the company.
The Indian government had told Maiden Pharmaceuticals to stop its production after the disaster in the Gambia when children died after consuming the cough syrup manufactured by the company. The factory situated close to the Indian Capital New Delhi alleged to have exported the syrup to the Gambia. WHO reported that its cough syrups exported to the Gambia may be linked to the deaths of dozens of children there.
India supplies 45% of all generic medicines to Africa. The incident claimed the lives of 69 children. India had doubled its pharmaceutical exports to Africa in the last decade to US$24.5 billion last fiscal year.
Indian authorities inspected the Maiden factory in the state of Haryana four times this month. They suspended all manufacturing activities there on grounds of deficiencies found in location inspection. The inquiry conducted by the state and federal authorities found that the manufacturing facility had violated 12 laws. Maiden’s main factory is in Sonipat district, Haryana, a state lying close to the national capital-New Delhi. A top official of the state government said that it was finding out what exactly happened in the Gambia, adding that India exercises stringent regulations in pharmaceutical manufacturing.
Read Also:
https://trendsnafrica.com/who-investigates-gambias-childrens-death-due-to-syrup-consumption/
https://trendsnafrica.com/the-usda-awards-28-5-to-support-gambia/
The government of India has formed a committee of four experts that would advise further action after examining and analysing adverse event reports shared by the WHO.
